A study, published in The New England Journal of Medicine, compared drug-eluting bioresorbable vascular scaffolds with drug-eluting metallic stents in percutaneous coronary interventions. Abbott ...

Please provide your email address to receive an email when new articles are posted on . Researchers randomly assigned 261 patients with chronic limb-threatening ischemia (CLTI) on a 2:1 basis to ...

Please provide your email address to receive an email when new articles are posted on . There were small increases in target lesion failure and device thrombosis within 3 years with a bioresorbable ...

SAN FRANCISCO, CA—Esprit BTK (Abbott Vascular), an everolimus-eluting resorbable scaffold, is safe and effective in the treatment of infrapopliteal chronic limb-threatening ischemia (CLTI) compared ...

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing ...

SAN DIEGO, CA, UNITED STATES, September 23, 2025 /EINPresswire.com/ -- REVA Medical, LLC, a leader in the development of bioresorbable vascular scaffolds (BRS) for ...

A decade already passed from the first use of bioresorbable vascular scaffold in percutaneous coronary interventions. The first studies - by using surrogate endpoints - showed some superiority of BRS ...

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry. Receive the the latest news, research, and presentations ...

Zeus, a global leader in advanced polymer solutions, announced today that it has developed Absorv™ XSE oriented tubing, the newest member of the company’s family of bioabsorbable products. Available ...

“Clinical development of our bioresorbable sirolimus-eluting scaffold for treating peripheral arterial disease (PAD) is proceeding ahead of schedule and achieving outstanding procedural results,” said ...

It was back to the drawing board for bioresorbable vascular scaffolds (BVS), to some degree, after the initially promising ABSORB series of trials dampened any enthusiasm for the coronary stent-like ...

MOUNTAIN VIEW, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating ...